Diurnal funds first trials for Chronocort drug delivery

Fusion IP’s portfolio company Diurnal has completed a £770,000 funding round that will enable its lead product, Chronocort, to complete its phase one trails and initiate its phase two trials.

Based in Cardiff, Diurnal is developing a novel approach to drug delivery that will help patients suffering from reduced cortisol and testosterone levels.

Chronocort is a delayed and sustained release therapy that delivers hydrocortisone in a manner that mimics the body’s normal circadian rhythm (the body’s natural 24-hour hormone cycle).

This therapeutic approach has the potential to help patients with deficiencies in steroid hormones and associated conditions by regulating metabolism, growth development, puberty, tissue function and mood.